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Population based studies show that primary headaches, such as migraine, 
are very common disorders.1 Similar accounts to vertigo and dizziness, 
which are are also symptoms frequently complained of.2 A significant 
proportion of patients report suffering these symptoms (headache, 
dizziness and/or vertigo) simultaneously and independently of each other. 
This especially accounts for migraine since up to 50% of these patients 
report that dizziness or vertigo accompanies their headaches at least once 
in a while.3,4 After a first attempt to introduce the term “vestibular migraine” 
(VM) was made in 19995 the International Headache Society (IHS) and the 
Bárány-Society (International Society for Neuro-Otology) just recently 
published a consensus paper with diagnostic criteria for VM.6,7 These 
criteria were adopted as appendix criteria in the beta version of the third 
International Classification of Headache Disorders (ICHD-3 beta) to support 
systematic research on the pathophysiology and treatment of VM.8 In 
the clinical setting, these new criteria may serve to aid practitioners in the 
assessment of patients with VM. While vertigo specialists generally accept 
the existence of this entity, between headache specialists the discussion is 
much more controversial. Some people favour this entity, others doubt the 
existence of the disorder. There is an ongoing debate whether the condition 
is a unique entity or it simply represents a subtype of common migraine, 
which also includes vestibular symptoms given that migraines often occurs 
with predominance of other accompanying symptoms such as excessive 
vomiting or phonophobia. In contrast there is wide agreement that the 
pathophysiology of the disorder/symptom complex remains uncertain.9 
Recent studies report that approximately two-thirds of patients 
experiencing vertigo or dizziness seek medical care because of their 
symptoms, but VM was diagnosed in only 20% of all patients.10 Interestingly, 
in routine clinical practice, clinicians reach multiple different 
interpretations of the symptom complex of headache and vertigo, and 
these interpretations are often speciality dependent. Neurologists were 
reported to diagnose VM in 82% of patients with this constellation, while 
only 64.5% of Ear, Nose, and Throat physicians made this diagnosis.10
Specific trials particularly addressing the treatment of VM are rare and 
most treatment guidelines are extrapolated from clinical trials on migraine 
with and without aura. This review summarizes the available data 
regarding specific treatment of VM.
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Methods
A Medline search with the search term “vestibular migraine” was performed 
in August 2015. The search returned 152 publications of which three were 
clinical trials. The term “vestibular AND migraine” resulted in 483 Medline 
hits of which 21 were clinical trials and 125 were marked review articles. 
Twenty-three publications were related to the specific treatment of VM. 
Due to the recent development of the consensus diagnostic criteria, the 
interpretation of this available data in the literature is difficult. It should be 
borne in mind that the patients enrolled in some of the studies would not 
fulfil the new diagnostic criteria for VM. Furthermore, some studies used 
a different terminology all together. The most common diagnoses used 
for the combination of migraine and vestibular symptoms were migrainous 
vertigo, vertiginous migraine, benign paroxysmal vertigo (of childhood), 
migraine-associated balance disturbance, and migraine-associated 
vertigo, besides VM.5 
Vestibular Migraine
In the above mentioned diagnostic criteria, VM is defined as episodes of 
vestibular symptoms of moderate or severe intensity lasting between 5 
minutes and 72 hours, of which at least 50% are associated with 
migrainous headache, photophobia, phonophobia and/or visual aura in 
subject with a current or past history of migraine without aura or migraine 
with aura (MwA). 
Approximately 30% of all VM attacks are not accompanied by headache.11–13 
In regard to the duration of attacks some studies partly contradict the 
diagnostic criteria, which may vary from a few seconds (10% of patients) to 
some minutes (30%), some hours (30%) and even up to a few days 
(30%).5,11,12,14 Only 10-30% of patients report vestibular symptoms with a 
duration between 5 and 60 minutes.5,13 In regard to the characteristics of the 
vertigo, a population-based survey found spontaneous rotatory vertigo 
(67%) to be the most frequent vestibular symptom followed by positional 
vertigo (24%).15 The vertigo itself may well change character within the 
attack, for example, an initial spontaneous rotatory vertigo can turn into a 
positional one or an illusion-of-movement type vertigo.16,17 Patients further 
describe an increased sensitivity to motion, especially in regard to head-
movements and fast-moving visual objects.18,19 During and even after an 
attack, gaze-induced nystagmus, saccadic pursuit (most often vertically), 
central positional nystagmus and slight horizontal or vertical spontaneous 
nystagmus may be observed.5 
Population-based studies conducted in Germany estimated the lifetime 
prevalence of migraine and vertigo as high as 7-16%.2,20 The lifetime 
prevalence of VM was estimated as 1% and the one-year prevalence as 
0.9%.15 A North American survey described the presence of dizziness or 
vertigo at nearly 50% of patients with migraine during a severe migraine 
attack.21 VM may occur in any period of life, although temporal delay to 
the first onset of migraine is frequent and leads to an emphasis in later 
periods of life.5,11,13,22 As in typical migraine, women are affected more 
frequently than men and familial clustering has been described.5,12,13,22,23 
VM was previously thought to be a subtype of MwA, but this association 
is controversial as some studies found a connection between MwA and 
VM, while others described patients with migraine without aura to have 
vestibular symptoms at least as often as MwA patients.5,12–14,24–26 It appears 
that in postmenopausal women the typical migraine headaches may be 
replaced by isolated episodes of vertigo and/or dizziness.27
From a clinical point of view, the clear cut differentiation from migraine 
with brainstem aura (previously called basilar-type migraine) is of 
significant importance since triptans are contraindicated in this condition. 
Less than 10% of patients with VM simultaneously meet the diagnostic 
criteria for basilar-type migraine.12,13 Diagnostic criteria for migraine with 
brainstem aura require at least two brainstem aura symptoms including 
dysarthria, vertigo, tinnitus, hypacusis, diplopia, ataxia or decreased level 
of consciousness, which are accompanied or followed by a typical 
migraine headache.8
Medical Therapy
Acute Treatment
There are only two randomized controlled clinical trials on the specific 
treatment of vestibular symptoms in migraineurs using triptans (see 
Table 1).28,29 One study investigated the efficacy of rizatriptan regarding 
Table 1: Attack Therapy—Treatment Options 
and Evidence
Drug Dose Study
Zolmitriptan 2.5 mg Randomized controlled trial28
Rizatriptan 10 mg Randomized controlled trial, motion sickness29
Table 2: Prophylactic Drug—Treatment Options 
and Evidence
Class Drug Dosage 
(oral)
Study-type
Beta-blockers Metoprolol 150 mg Retrospective cohort analysis30
100-200 mg Retrospective cohort analysis32
Propranolol 160 mg Retrospective cohort analysis30
40-160 mg Retrospective cohort analysis31,32
40-160 mg Prospective, open-label, 
randomized, controlled trial41
Anti-epileptic 
agents
Valproic Acid 600 mg Retrospective cohort analysis30
600 mg Cohort study, vestibulo-ocluar-
reflex33
Topiramate 50 mg Retrospective cohort analysis30
50-100 mg Open-label, chart review43
Lamotrigine 75 mg Retrospective cohort analysis30
100 mg Retrospective, open-label34
Antidepressants Amitriptyline 100 mg Retrospective cohort analysis30 
10 mg Retrospective cohort analysis32
Nortriptyline 25-75 mg Open-label, chart review43
Venlafaxine 37.5-150 mg Prospective, open-label, 
randomized, controlled trial41
Calcium channel 
blockers
Flunarizine 5 mg Retrospective cohort analysis30
5-10 mg Retrospective, open-label32
5-10 mg Open-label, post-marketing38,39
Cinnarizine 37.5-75 mg 
oral
Retrospective, open-label36
Others Magnesium 400 mg Retrospective cohort analysis30
Butterbur 
Extract
50 mg Retrospective cohort analysis30
Clonazepam 0,25-1 mg Retrospective cohort analysis32
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the vertigo symptoms only in measuring the motion sickness following a 
complex vestibular stimulus (off-vertical axis rotation). The study 
recruited 25 migraine patients (23 females, 31.0 ± 7.8 years) with or 
without migraine-related dizziness. Fifteen subjects experienced 
vestibular-induced motion sickness after pre-treatment with placebo and 
thirteen of those had decreased motion sickness when pre-treated with 
rizatriptan (p<0.02). This positive effect has to be put into perspective 
since it was not seen after exposure to a more intense provocative 
stimulation. With regard to mechanism of action, the authors suggested 
that rizatriptan, a serotonin-agonist, may influence the serotonergic 
vestibular-autonomic projections.29 Another study suggested a benefit 
from zolmitriptan 5 mg in “migrainous vertigo”. The explanatory power of 
this study is limited, however, since only ten patients were recruited and 
only 17 attacks were analyzed. The response to zolmitriptan was 38% 
(3 of 8 episodes), whereas in the placebo group a positive effect was 
observed in only 22% (2 of 9 episodes).28 
Prophylactic Treatment
Regarding prophylactic treatment of VM, no data from double-blind, placebo-
controlled trials are published thus far (see Table 2). Most therapeutic 
recommendations for VM are currently based on the guidelines for migraine 
with and without aura. This seems a reasonable approach since a large 
retrospective cohort evaluation of 100 patients (21–72 years) analyzing 
standard prophylactic migraine treatment in VM patients reported a positive 
outcome.30 The patients on prophylactic treatment showed a decrease in 
duration, intensity, and frequency of vertigo as well as its associated features 
(p<0.01). The most frequently used drug-class in this observational study 
were beta-blockers taken by 49 patients (69% on metoprolol, median dose 
150 mg; 31% on propranolol, median dose 160 mg). Second most frequent 
drug-class were anticonvulsants such as sodium-valproate (median dose 
600 mg) and topiramate (median dose 50 mg) each with 6 patients, and 
lamotrigine (3 patients, median dose 75 mg). Other drugs were butterbur (4 
patients, median dose 50 mg), amitriptyline (2 patients; 75/100 mg); 
flunarizine (1 patient: 5 mg), magnesium (3 patients; median dose 400 mg). 
A second retrospective study investigating prophylactic treatment also 
indicated a positive effect in patients with VM.31 This study also reported a 
correlation between the improvement of vestibular symptoms and the 
improvement of headache. 
In a third retrospective study 33 patients with migraine and recurrent 
vertiginous attacks were evaluated.32 In the analysis of vertigo frequency, 
complete resolution was reported in 58% of the patients (19/33). A 
reduction of more than 50% was seen in nearly 25% (8/33), and only 18% 
of the patients reported a reduction of less than 50% or no response 
(5+1/33). In another small study specifically investigating the effect of 
sodium valproate on the vestibulo-ocular reflex, sodium valproate 
affected neither vestibulo-ocular responses nor vestibular complaints but 
was effective in reducing migraine attacks in 8 of the 12 patients.33
A retrospective, open-label study investigated the efficacy of lamotrigine 
in 19 patients (13 women). Monthly vertigo-attack frequency was reduced 
from 18.1 to 5.4 and headache frequency from 8.7 to 4.4, which was not 
statistically significant. It appears that lamotrigine is more effective for 
vestibular symptoms than for headaches.34 This is especially interesting 
since it was previously shown that lamotrigine is more effective for aura 
than for migraine headache.35 
Calcium-channel-blockers appear to be a reasonable treatment choice in 
VM since they are frequently used in migraine as well as vertigo. In a 
retrospective, single-center, open-label, study cinnarizine was tested 
regarding its effects on VM and migraine associated with vertigo.36 The 
study included 24 patients (23 female) with VM and 16 (12 female) 
suffering from basilar-type migraine. Significant reduction was seen in 
mean vertigo frequency as well as in mean headache frequency, duration 
and intensity (p < 0.001). 
For the calcium channel antagonist, flunarizine there is one randomized 
controlled trial evaluating the efficacy of flunarizine 10 mg in 48 “migrainous 
vertigo” patients in comparison to standard care with regular vestibular 
exercises and symptomatic use betahistine 16 mg, three times a day (TDS) 
for 2 days and paracetamol 1 g as needed (PRN).37 Flunarizine led to 
reduction of vertigo frequency (p=0.010) and severity (p=0.046). In contrast, 
the headaches (severity and frequency) were not significantly reduced. 
In two large open-label post-marketing studies, flunarizine was reported 
to be effective for migraine (compared to propranolol) and vertigo 
(compared with betahistine).38,39 The results from these big cohorts cannot 
be directly related to the response to VM, since both studies evaluated 
the two symptoms independantly of each other. A fourth analysis of this 
agent evaluated the efficacy of flunarizine and propranolol in VM and 
found both drugs to be comparably effective. While 68% of the patients 
responded to flunarizine (p<0.001) improvement of symptoms was seen 
in 73% of the patients on propranolol (p<0.001).40
A recent prospective, randomized, controlled active comparator study 
investigated the effectiveness of venlafaxine and propranolol for the 
prophylaxis of VM in 64 patients.41 Endpoints were the “Dizziness Handicap 
Inventory”, the “Vertigo Severity Score” and the number of vertiginous 
attacks. At 4 months all endpoints showed significant improvement and 
treatment effects were similar in both groups (p>0.05). Additionally, “Beck 
Depression Inventory”-testing was performed which only improved in the 
venlafaxine arm of the study. 
Even for drugs not specially tested in migraine with or without aura or those 
previously shown to be ineffective in these conditions, positive data exist 
regarding treatment of VM; these drugs include benzodiazepines, pizotifen, 
dothiepin, selective serotonin reuptake inhibitors (SSRI), and acetazolamide.32 
However, data are insufficient to derive therapeutic recommendation for 
any one of those medications. Furthermore, these studies were performed 
prior to the current definition of VM and inconstant criteria were used 
across studies. Hopefully this ambiguity will no longer feature 
in future studies and the recent consensus diagnostic criteria are likely to 
lead to more comparable and higher quality studies.
Non-medical Treatment Options 
An Australian study investigated the effect of a structured nine-week 
vestibular rehabilitation exercise programme as add-on to medication or 
as stand-alone treatment.42 Thirty-six patients with daily vestibular 
symptoms (VM 20, vestibular impairment 16) attended five therapy 
appointments during a six-month period. Although starting from a 
different level of impairment, both groups benefited comparably from this 
intervention. The effect was not found to differ between different 
medication regimes, which led the authors to conclude that the 
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rehabilitation therapy may be effective in VM regardless of the medical 
prophylactic therapy used. 
There is only very limited data on the effect of behavioural therapies and 
modification on VM. One study investigated the cessation of caffeine in 34 
patients.43 Approximately 14% of patients reported an improvement of 
their symptoms. To put this into perspective, topiramate reduced 
symptoms in 25% and nortriptyline in nearly 50% of patients.
Treatment Recommendations and Conclusions
Due to the lack of high quality trials in this condition the treatment 
recommendations for VM are currently similar to those for migraine with 
or without aura. Some of the following treatment recommendations are 
based on the authors’ experience. 
The available literature suggests zolmitriptan (5 mg) as first choice acute 
therapy for VM. Rizatriptan may also be used and it is likely that the other 
triptans are just as effective. Patients with nausea and/or vomiting may 
benefit more from non-oral applications (i.e., nasal spray, or subcutaneous 
injections). If triptans are not suitable, symptomatic therapy with non-
steroidal anti-inflammatory drugs, acetylsalicylic acid, metoclopramide or 
dimenhydrinate may be another option, especially since the latter three 
are available in intravenous formulations (acetylsalicylic acid 1000 mg, 
metoclopramide 10 mg or dimenhydrinate 62.5 mg). Triptans should not be 
used in patients fulfilling criteria for VM and migraine with brainstem aura. 
Data regarding prophylactic medications for VM are not sufficiently robust 
to deviate from the guidelines for treatment of migraine with or without 
aura. The agents that can be considered include beta-blockers (propranolol 
80-240 mg, metoprolol 50-200 mg, bisoprolol 5-10 mg), calcium channel 
blockers (flunarizine 5-10 mg) and anticonvulsants (topiramate 50-100 mg, 
sodium-valproate 1000-1500 mg). In patients suffering chronic migraine 
with vestibular symptoms (15 headache days per month, of which at least 
8 are migrainous, lasting for longer than 3 months) consider topiramate or 
at least two courses of onabotulinumtoxin type A injections,44 albeit that 
no data exist for the treatment of VM specifically. If depression is comorbid 
with VM, amitriptyline may be a reasonable choice. Patients with 
predominant vertigo or dizziness with typical aura duration and those who 
simultaneously fulfil criteria for brainstem aura might be successfully 
treated with lamotrigine (25-100 mg).34 
Hitherto, controlled data for the treatment of VM are sparse; while some 
data from small randomized controlled trials exist for the attack treatment, 
no data from high quality trials exist for the prophylactic regimes. 
Retrospective analyses and open label studies suggest, that the 
established treatments for migraine with and without aura may be 
effective in VM as well. However, there remains an uncertainty whether 
one of those treatment options is superior to others and whether more 
specific treatment options exist. An ongoing multicenter randomized 
placebo-controlled trial (metoprolol 95 mg vs. placebo) called PROVEMIG-
trial is currently underway. ■
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